DLDiane Liu

Diane Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diane Liu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CoxPhLb: An R Package for Analyzing Length Biased Data under Cox Model

    by Hyun Lee Chi, Heng Zhou, Jing Ning, D. Liu Diane, Yu Shen

    Data subject to length-biased sampling are frequently encountered in various applications including prevalent cohort studies and are considered as a special case of left-truncated data under the stationarity assumption. Many semiparametric regression methods have been proposed for length-biased data to model the association between covariates and the survival outcome of interest. In this paper, we present a brief review of the statistical methodologies established for the analysis of length-biased data under the Cox model, which is the most commonly adopted semiparametric model, and introduce an R package CoxPhLb that implements these methods. Specifically, the package includes features such as fitting the Cox model to explore covariate effects on survival times and checking the proportional hazards model assumptions and the stationarity assumption. We illustrate usage of the package with a simulated data example and a real dataset, the Channing House data, which are publicly available.


  • Open Access

    Chronic Non-Malignant Pain in Patients with Cancer Seen at a Timely Outpatient Palliative Care Clinic

    by David Hui, Eman Abdelghani, Joseph Chen, Shiva Dibaj, Donna Zhukovsky, Rony Dev, Kimberson Tanco, Ali Haider, Ahsan Azhar, Akhila Reddy, et al.

    Palliative care is seeing cancer patients earlier in the disease trajectory with a multitude of chronic issues. Chronic non-malignant pain (CNMP) in cancer patients is under-studied. In this prospective study, we examined the prevalence and management of CNMP in cancer patients seen at our supportive care clinic for consultation. We systematically characterized each pain type with the Brief Pain Inventory (BPI) and documented current treatments. The attending physician made the pain diagnoses according to the International Association for the Study of Pain (IASP) task force classification. Among 200 patients (mean age 60 years, 69% metastatic disease, 1-year survival of 77%), the median number of pain diagnosis was 2 (IQR 1–2); 67 (34%, 95% CI 28–41%) had a diagnosis of CNMP; 133 (67%) had cancer-related pain; and 52 (26%) had treatment-related pain. In total, 12/31 (39%) patients with only CNMP and 21/36 (58%) patients with CNMP and other pain diagnoses were on opioids. There was a total of 94 CNMP diagnoses among 67 patients, including 37 (39%) osteoarthritis and 20 (21%) lower back pain; 30 (32%) were treated with opioids. In summary, CNMP was common in the timely palliative care setting and many patients were on opioids. Our findings highlight the need to develop clinical guidelines for CNMP in cancer patients to standardize its management.


  • Open Access

    Cellular Oxidative Stress in Pediatric Leukemia and Lymphoma Patients Undergoing Treatment Is Associated with Protein Consumption

    by Margaret Raber, Jimin Wu, Hayley Donnella, Phillip Knouse, Mayurika Pise, Mark Munsell, Diane Liu, Joya Chandra

    Over and under nutrition are associated with worse outcomes for children with leukemia and lymphoma; however, the molecular basis for this clinical observation is not well understood. Many chemotherapeutics used for leukemia treatment are known to generate oxidative stress in vitro; therefore, we evaluated redox status and diet in pediatric leukemia patients during therapy in order to ascertain relationships between nutrition and oxidative stress. Dietary intake and redox measures in peripheral blood mononuclear cells from 32 pediatric leukemia and lymphoma patients were collected over six months during treatment. Baseline measures when patients were off chemotherapy and subsequent assessments were collected after one, two and six months. Oxidative stress increased over time in all patients, consistent with chemotherapy-induced redox effects. Older and younger children showed significantly different baseline levels of reactive oxygen species, which increased over time in all age ranges. Diet was assessed at points proximal to oxidative stress measurements and revealed a novel association with consumption of animal protein, vegetable protein, and total protein intake. Our findings demonstrate that chemotherapy increases oxidative stress in pediatric leukemia patients, and raises the possibility that dietary protein or altered protein metabolism could contribute to clinical outcomes.


  • (S016) Erlotinib May Enhance Radiation Effects in Patients With Stage III Non-small-cell Lung cancer

    by Ritsuko Komaki, Pamela K. Allen, Xiong Wei, George R. Blumenschein, Michael O'Reilly, Xi Ming Tant, J.J. Lee, James Welsh, Ignacio I. Wistuba, Diane D. Liu, et al.

  • Open Access

    Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer

    by Hye-Young Min, Hye Jeong Yun, Ji-Sun Lee, Hyo-Jong Lee, Jaebeom Cho, Hyun-Ji Jang, Shin-Hyung Park, Diane Liu, Seung-Hyun Oh, J. Jack Lee, et al.

    Therapeutic interventions in the insulin-like growth factor receptor (IGF-1R) pathway were expected to provide clinical benefits; however, IGF-1R tyrosine kinase inhibitors (TKIs) have shown limited antitumor efficacy, and the mechanisms conveying resistance to these agents remain elusive. The expression and activation of the IGF-1R and Src were assessed via the analysis of a publicly available dataset, as well as immunohistochemistry, Western blotting, RT-PCR, and in vitro kinase assays. The efficacy of IGF-1R TKIs alone or in combination with Src inhibitors was analyzed using MTT assays, colony formation assays, flow cytometric analysis, and xenograft tumor models. The co-activation of IGF-1R and Src was observed in multiple human NSCLC cell lines as well as in a tissue microarray (n = 353). The IGF-1R and Src proteins mutually phosphorylate on their autophosphorylation sites. In high-pSrc-expressing NSCLC cells, linsitinib treatment initially inactivated the IGF-1R pathway but led a Src-dependent reactivation of downstream effectors. In low-pSrc-expressing NSCLC cells, linsitinib treatment decreased the turnover of the IGF-1R and Src proteins, ultimately amplifying the reciprocal co-activation of IGF-1R and Src. Co-targeting IGF-1R and Src significantly suppressed the proliferation and tumor growth of both high-pSrc-expressing and low-pSrc-expressing NSCLC cells in vitro and in vivo and the growth of patient-derived tissues in vivo. Reciprocal activation between Src and IGF-1R occurs in NSCLC. Src causes IGF-1R TKI resistance by acting as a key downstream modulator of the cross-talk between multiple membrane receptors. Targeting Src is a clinically applicable strategy to overcome resistance to IGF-1R TKIs.


    • 1 December 2002
      • Vol. 8  (12) , 3669-75

    Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.

    by Yoon Soo Chang, Luo Wang, Diane Liu, Li Mao, Waun Ki Hong, Fadlo R Khuri, Ho-Young Lee

    The activities of insulin-like growth factors (IGFs) in regulating cell proliferation,differentiation, and apoptosis are modulated by a family of high-affinity specific IGF-binding proteins (IGFBPs), especially IGFBP-3, the most abundant IGFBP in circulation. Hypermethylation of the promoter represses the expression of the IGFBP-3 gene. The purpose of this study was to determine whether the methylation status of IGFBP-3 promoter influences the prognosis of non-small cell lung cancer (NSCLC). Eighty-three patients with pathological stage I NSCLC who had undergone curative surgery were investigated for promoter hypermethylation of IGFBP-3 by methylation-specific PCR. Statistical analyses, all two-sided, were performed to determine the prognostic effect of methylation status of the IGFBP-3 promoter on various clinical parameters. IGFBP-3 was the only molecular parameter tested on these tissues in this study. Hypermethylation of the IGFBP-3 promoter was found in 51 (61.5%) of the 83 tumors. The clinicopathological factors, such as age, histological type, histological grade, gender, and smoking status, of corresponding patients, did not exhibit statistically significant association with the methylation status of IGFBP-3 promoter. However, patients with a hypermethylated IGFBP-3 promoter had a significantly lower 5-year disease-specific, disease-free, and overall survival rate than did those without a methylated IGFBP-3 promoter (53.1% versus 86.1%, P = 0.006; 36.5% versus 76.2%, P = 0.007; and 38.9% versus 64.0%, P = 0.022, respectively). Moreover, multivariate analysis indicated that hypermethylation of the IGFBP-3 promoter was the only independent predictor for disease-free and disease-specific survival among the clinical and histological parameters tested. Hypermethylation of the IGFBP-3 promoter, as measured by methylation-specific PCR, is a frequent phenomenon and strongly associated with poor prognosis among patients with stage I NSCLC.


    • 1 December 2002
      • Vol. 8  (12) , 3796-802

    Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.

    by Yoon Soo Chang, Gu Kong, Shihua Sun, Diane Liu, Adel K El-Naggar, Fadlo R Khuri, Waun Ki Hong, Ho-Young Lee, Koo Gong

    The activities of insulin-like growth factors (IGFs), including mitogenic and antiapoptotic properties, are modulated by a family of high-affinity insulin-like growth factor-binding proteins (IGFBPs), of which IGFBP-3 is the major serum carrier protein. Even though it is well known that IGFBP-3 plays an important role in cell proliferation, the expression of IGFBP-3 and its significance in primary non-small cell lung cancer (NSCLC) samples are unknown. This study explored IGFBP-3 expression in tumor samples from 74 patients with a diagnosis of pathological stage I NSCLC to determine if the expression status of IFGBP-3 influences the prognosis of patients with NSCLC. Two-sided statistical analyses were performed to correlate the clinical parameters and the prognostic effect with the IGFBP-3 expression level in this cohort. Reduced IGFBP-3 expression was found in 42 (56.8%) of 74 samples, and it was more frequent in large cell carcinoma than in squamous cell carcinoma and adenocarcinoma, although this difference was not statistically significant. This phenomenon was not associated with the other clinicopathological parameters tested, such as age, sex, histological grade, and smoking history. Significant statistical correlation between IGFBP-3 expression and disease-specific survival was noted (P = 0.019 by log-rank test). Although statistically nonsignificant, patients with decreased IGFBP-3 expression had shorter overall, disease-free, and event-free survival rates than did patients with normal IGFBP-3 expression. In a multivariate analysis using IGFBP-3 expression and other clinicopathological parameters, the level of IGFBP-3 expression remained as an independent factor for predicting a shorter disease-specific survival probability (P = 0.020). Our work demonstrates that down-regulation of IGFBP-3 is a frequent event in stage I NSCLC and correlates with the disease-specific survival probability of patients with stage I NSCLC. These results suggest that IGFBP-3 functions as a tumor suppressor and plays an important role in determining biological aggressiveness in early NSCLC.


    • 1 December 2002
      • Vol. 11  (12) , 1605-10

    Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions.

    by Vassiliki A Papadimitrakopoulou, Diane D Liu, Li Mao, Dong M Shin, Adel El-Naggar, Heladio Ibarguen, J Jack Lee, Waun K Hong, Walter N Hittelman

    To identify tissue biomarkers that might be used to assess an individual's cancer risk and response to chemoprevention, we studied in dysplastic lesions of the larynx and the p.o. cavity, a series of biomarkers extensively used in previous chemoprevention trials, including chromosome polysomy (CP), proliferative status, p53 expression and gene mutations, and loss of heterozygosity at 9p, 3p, and 17p. Biopsies from 32 participants in a prospective chemoprevention trial using 13-cis-retinoic acid, IFN-alpha, and alpha-tocopherol for 12 months (20 with vocal cord and 12 with p.o. cavity lesions) were analyzed for p53 and Ki-67 expression by immunohistochemistry, loss of heterozygosity by PCR amplification, p53 mutations by PCR-based direct sequencing, and CP by in situ hybridization. High CP (> or =4% cells with more than three chromosome copies per nucleus) was more common in p.o. (8 of 10) than laryngeal lesions (4 of 16; P = 0.01), and so was a combination of CP > or = 4% and parabasal layer p53 labeling index > or = 0.2 (P = 0.02). Low CP was a significant predictor of complete histological response (8 of 14 cases with low versus 1 of 12 cases with high CP; P = 0.01). A trend for histological progression or cancer development was observed in cases with high CP and parabasal layer p53 labeling index. Low CP, more frequently observed in laryngeal lesions, appears to be a predictor of response to chemoprevention and could be used as a screening tool to identify suitable candidates for such approaches. Further investigation of biological parameters of response and cancer risk is warranted.


    • 1 May 2002
      • Vol. 8  (5) , 1178-84

    Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

    by Jean-Charles Soria, Ho-Young Lee, Janet I Lee, Luo Wang, Jean-Pierre Issa, Bonnie L Kemp, Diane D Liu, Jonathan M Kurie, Li Mao, Fadlo R Khuri

    The PTEN gene at chromosome 10q23.3 is a tumor-suppressor genethat is inactivated in several types of human tumors. Althoughmutation and homozygous deletion are the most commonmechanisms of PTEN inactivation, promoter methylation and translational modification can also account for PTEN silencing. The aim of this study was to investigate the expression of PTEN protein in primary non-small cell lung cancer (NSCLC) samples and to investigate the promoter methylation status of the gene in a panel of NSCLC cell lines as well as primary tumors. We analyzed PTEN expression by immunohistochemistry in tissue samples from 125 patients with early-stage NSCLC. We also evaluated PTEN promoter methylation status by methylation-specific PCR in 20 microdissected PTEN-negative primary tumors from among the last specimens as well as in a panel of 16 NSCLC cell lines. Western and Northern blotting were performed in the same panel of NSCLC cell lines. Thirty (24%) of the 125 specimens showed a lack of staining for PTEN. PTEN methylation was detected in 7 (35%) of the 20 PTEN-negative NSCLC samples and in none of the 10 PTEN-positive NSCLC samples that were microdissected. Furthermore, PTEN methylation was observed in 11 (69%) of the 16 NSCLC cell lines tested. PTEN mRNA expression was increased in the NCI-H1299 cell line by in vitro treatment with the demethylating agent 5-aza-2'-deoxycytidine. PTEN methylation was well correlated with PTEN expression in NSCLC cell lines by Western and Northern blot (P = 0.025). Although genetic alterations of the PTEN gene are rare in NSCLC, loss of PTEN protein is not an uncommon event in early-stage NSCLC. Lack of PTEN expression may be partially explained by promoter methylation.


    • 15 January 2002
      • Vol. 62  (2) , 351-5

    Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers.

    by Jean-Charles Soria, Marivonne Rodriguez, Diane D Liu, J Jack Lee, Waun Ki Hong, Li Mao

    Promoter hypermethylation plays an important role in the inactivation of tumor suppressor genes during tumorigenesis. Recent data suggest that such epigenetic abnormality may occur very early in lung carcinogenesis. To determine the extent of promoter hypermethylation in early lung tumorigenesis, we analyzed promoter methylation status of the p16, death-associated protein kinase (DAPK) and glutathione S-transferase P1 (GSTP1) genes using methylation-specific PCR in bronchial brush samples obtained from 100 former smokers enrolled in a chemoprevention clinical trial. We found that 17% of the samples showed methylation for p16 and 17% the same for DAPK, whereas only 6% of the samples displayed methylation for GSTP1. A total of 32% of the samples had methylation in at least one of the three genes tested, and 8% of the samples had methylation in two genes. The methylation status of p16 was correlated with that of DAPK (P = 0.04, Fisher's exact test). p16 methylation was higher in former smokers with a history of previous cancer than in former smokers without a history of cancer (P = 0.04, Fisher's exact test), and methylation of DAPK was detected more frequently in older patients than it was in younger patients (P = 0.01, Wilcoxon rank-sum test). Surprisingly, no correlation was found between methylation in any of these genes and the smoking characteristics of the individuals analyzed (packs per day, pack-years, smoking years, quitting years). The precise meaning of methylated genes in the bronchial brush samples of former smokers must be sought by means of careful follow-up of these individuals.